MRSN: Mersana Therapeutics Inc

MRSN News

• 13:55 Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet
• 15:55 Truist Securities slashes Mersana stock price target to $36 from $250
• 11:45 Guggenheim lowers Mersana stock price target to $30 from $125
• 17:49 Mersana stock price target raised to $17 from $6 at BTIG
• 15:44 Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript
• 12:15 Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
• 11:28 Mersana Therapeutics earnings missed by $4.71, revenue fell short of estimates
• 21:10 Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
• 23:20 VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
• 11:45 Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
• 12:15 Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
• 12:46 Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested - TipRanks.com
• 14:47 Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan
• 13:42 Mersana Therapeutics to implement 1-for-25 reverse stock split Friday
• 12:49 Mersana Therapeutics to implement 1-for-25 reverse stock split
• 12:28 Mersana reports promising Phase 1 ADC trial results
• 19:01 Mersana Therapeutics at TD Cowen Summit: Strategic Updates on Oncology Innovations
• 12:12 Mersana Therapeutics to Present at Upcoming Investor Conferences
• 20:04 Truist raises Mersana stock target to $10, maintains Buy rating
• 13:32 CORRECTION - Mersana Therapeutics Provides Business Update and Announces  First Quarter 2025 Financial Results
• 11:32 Mersana Therapeutics Provides Business Update and Announces  First Quarter 2025 Financial Results
• 11:22 Mersana Therapeutics earnings matched, revenue fell short of estimates
• 18:00 Walmart, Deere, Applied Materials set to report earnings Thursday